Anthera Pharmaceuticals Income Tax

Anthera Pharmaceuticals's income tax stands at $-14M as of March 2018. That compares with $-1.3M in the prior-year period — down 956.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Anthera Pharmaceuticals reported $-14M in income tax versus $-1.3M a year earlier — a 956.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-1.3M in the prior-year period — down 956.8% year over year. Sustained growth in income tax can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Anthera Pharmaceuticals's income tax evolved across reporting periods, while the comparison chart places ANTH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, income tax is commonly used to spot outliers. Anthera Pharmaceuticals's reading of $-14M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.